Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Finished Goods (2020 - 2025)

Fortress Biotech has reported Finished Goods over the past 6 years, most recently at $10.0 million for Q1 2025.

  • Quarterly results put Finished Goods at $10.0 million for Q1 2025, up 70.95% from a year ago — trailing twelve months through Mar 2025 was $10.0 million (up 70.95% YoY), and the annual figure for FY2024 was $11.4 million, up 128.21%.
  • Finished Goods for Q1 2025 was $10.0 million at Fortress Biotech, down from $11.4 million in the prior quarter.
  • Over the last five years, Finished Goods for FBIO hit a ceiling of $11.4 million in Q4 2024 and a floor of $4.3 million in Q4 2021.
  • Median Finished Goods over the past 5 years was $7.1 million (2023), compared with a mean of $7.3 million.
  • Biggest five-year swings in Finished Goods: surged 205.56% in 2021 and later crashed 35.56% in 2023.
  • Fortress Biotech's Finished Goods stood at $4.3 million in 2021, then surged by 80.4% to $7.7 million in 2022, then plummeted by 35.56% to $5.0 million in 2023, then surged by 128.21% to $11.4 million in 2024, then decreased by 11.91% to $10.0 million in 2025.
  • The last three reported values for Finished Goods were $10.0 million (Q1 2025), $11.4 million (Q4 2024), and $8.7 million (Q3 2024) per Business Quant data.